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Abstract 
This study aimed to compare the effect of beta blocker dose and heart rate on mortality in 
patients with heart failure with reduced ejection fraction (HFrEF). The Veteran Affairs databases 
were queried to identify all patients diagnosed with HFrEF based on ICD-9 codes from 2007-
2015 and beta blocker (carvedilol or metoprolol succinate) use. 36,168 patients on low dose 
beta blocker were then matched with 36,168 patients on high dose beta blocker using 
propensity score matching. The impact of beta blocker dose and heart rate was assessed on 
overall mortality using Cox proportional hazard model.  After dividing average heart rate into 
separate quartiles and adjusting for patient characteristics, high beta blocker dose was 
associated with lower overall mortality as compared to a low dose of beta blocker (HR:0.75, 
95% CI:0.73-0.77,p<0.01) independent of the heart rate achieved. The results held for all 4 
quartiles of average heart rate. A higher beta blocker dose or a lower heart rate were both 
independently and jointly associated with lower mortality for all quartiles of heart rate. In 
conclusion, higher dose of beta blocker therapy and a lower achieved heart rate were both 
independently associated with a reduction in mortality in HFrEF patients.  
Keywords: Heart failure with reduced ejection fraction, beta blocker, heart rate, veterans 
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As per current major societal guidelines, beta blocker therapy is indicated in the treatment all 
patients with heart failure with reduced ejection fraction (HFrEF) with left ventricular (LV) 
ejection fraction (EF) ≤ 0.40.(1-3) The 3 beta blockers currently approved for such patients are 
carvedilol, metoprolol succinate and bisoprolol. Of these, carvedilol and metoprolol succinate 
are the most commonly used in the United States. While a beta blocker can reduce the heart 
rate (HR), the benefit of these medications in HF patients may not be due entirely to their HR 
lowering mechanism.(4) Two meta-analyses suggested that HR reduction may be the major 
contributor to the clinical benefits of beta blocker therapy rather than target dose in systolic 
heart failure.(5, 6) Data from HF-ACTION trial showed that a higher beta blocker dose was 
associated with better outcomes regardless of baseline HR.(7) The relative importance of 
lowering HR compared to titrating dose to maximum tolerated levels remains unclear. In this 
large retrospective study, the aim was to determine the relative importance of lowering HR 
compared to beta blocker dose in reducing mortality in patients with HFrEF.  
Methods 
Data of patients diagnosed with HF either as an inpatient or an outpatient from January 
1st 2007 to January 27th 2015 were retrieved from Veterans Affairs (VA) Corporate Data 
Warehouse (CDW) through the Veterans Administrations Informatics and Computing 
Infrastructure (VINCI). Patients who did not refill the beta blocker through a VA outpatient 
pharmacy and those who did not take the medication for ˃30 days were excluded. Follow up 
duration was defined as the interval from the initial VA outpatient pharmacy fill date to death or 
to the end of the study. Mortality data was obtained through the VA’s death registry. All patient’s 
comorbidities were based on inpatient or outpatient International Classification of Diseases 9th 
Revision (ICD-9) codes.  Implantable cardioverter-defibrillator (ICD) implantation was defined by 
Current Procedural Terminology (CPT) codes and ICD-9 codes.   
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Patients with missing, inconsistent, or seemingly erroneous values in variables such as 
sex, treatment dates, death, HR, and average daily dose of beta blocker were removed. 
Patients who died within 30 days of treatment were excluded from the study. Patients who 
switched beta blocker therapy at any time were also excluded from the study. 
Out of all the patients with HFrEF at the VA treated who did not cross over treatment 
165,224 patients were reviewed. After removing patients due to missing data, duration of 
therapy ˂30 days, and average heart rate ˂45 bpm our sample size of patients (metoprolol 
succinate or carvedilol) during their treatment was 114,010 with 36,168 patients using a low 
dose and 77,842 patients using high dose of the beta blocker. Following Fiuzat et al., the beta 
blocker dose was classified as “High Dose Beta Blocker” for dose ≥25 mg of carvedilol daily 
(and ≥100 mg of metoprolol succinate.(7) “Low Dose Beta Blocker” was defined as those ˂25 
mg carvedilol daily (or ˂100 mg metoprolol daily). In Figure 2, the sample was divided into 4 
quartiles of average heart rate measured during treatment.  The Cox proportional hazard 
models were performed after adjusting for clinical characteristics and medications listed in Table 
1.  
The beta blocker dose was a dependent variable, and it was used as propensity score 
matching with replacement method to reduce heterogeneity in baseline characteristics, average 
heart rate, and comorbidities. This method identified patients who were taking a low beta 
blocker dose that were comparable in their characteristics with high dose patients. The 
combinations of beta blocker dose and quartiles of heart rate were plotted using the Kaplan 
Meier survival estimate. Follow-up time and censored observations were analyzed by using Cox 
proportional hazard model to assess the effects of patients taking high doses of beta blocker on 
overall mortality. The robust standard errors were used for all our analysis. The matched sample 
was analyzed with and without adjustments of patient characteristics and comorbidities. 
Regression adjustment estimation technique was used on the matched data to estimate the 
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average treatment effect. Sub-sample analysis of metoprolol and carvedilol groups was 
performed to test if the dose on top of beta blocker had any differential impact on the overall 
mortality. The Cox proportional hazard models were separately analyzed using all 4 quartiles of 
heart rate. We also applied average treatment effect to the matched data using regression 
adjustment estimation technique, which takes the averages of predicted outcomes to measure 
the treatment effect. All statistical analyses were performed using STATA 15.1. A p value ˂ 0.01 
was considered statistically significant.  
RESULTS 
The average follow-up duration was 1192 days. Shown in Figure 2, the 1st, 2nd, 3rd, 
and 4th quartile average heart rate on treatment for the matched sample were 64 beats/min, 71 
beats/min, 77 beats/min, and 87 beats/min respectively.  
From the total sample, 36,168 of low dose beta blocker patients were matched with as 
many high dose beta blocker patients. Table 1 shows the average baseline characteristics of 
sample taking either metoprolol succinate or carvedilol beta blocker by dose before and after 
matching. The characteristics appear to be statistically different across beta blocker dose before 
matching. However, after matching almost all the covariates were not statistically different from 
each other between low and high beta blocker dose.  
Figure 1 illustrates the Kaplan Meier survival estimate plots of high versus low beta 
blocker dose, with a higher survival rate in patients on a high dose beta blocker. Figure 2 shows 
the Kaplan Meier survival estimate plots of heart rate quartiles on our matched sample. Patients 
with a lower heart rate had a higher survival rate. Figure 3 shows the Kaplan Meier survival 
plots of beta blocker dose by quartiles of average heart rate on treatment. The patients with a 
lower heart rate while taking a high dose beta blocker had better survival.  
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Table 2 shows the unmatched and matched hazard ratio of beta blocker dose and also 
by type of beta blocker on mortality. Patients on a high dose of beta blocker were associated 
with lower overall mortality as compared to a low dose of beta blocker (HR: 0.74, 95% CI: 0.73-
0.76, p <0.01). The results were consistent even after adjusting for patient characteristics and 
comorbidities (HR: 0.75, 95% CI: 0.73-0.77, p<0.01). They remained consistent for both 
metoprolol succinate (HR: 0.88, 95% CI: 0.85-0.91, p<0.01) and carvedilol (HR: 0.65, 95% CI: 
0.63-0.67, p<0.01) with average daily dose of 103mg and 18mg respectively.  The improved 
survival of carvedilol over metoprolol succinate is consistent to our previous study.(8) 
From the treatment effects model, we find that the estimated average time to mortality 
when all matched sample were treated using low dose was 6.6. When the entire matched 
sample were treated with high dose of beta blocker, the average time to death was estimated to 
increase by 1.35 years (or 20% increase) than when all matched sample were treated using low 
dose of beta blocker.  
Table 3 shows the relative hazard ratios across different combinations of beta blocker 
dose and heart rate quartiles after adjusting for age, sex, and comorbidities. For the unadjusted 
columns in the table, the baseline (HR=1) was defined as patients with high beta blocker dose 
and in first quartile of heart rate. The higher the heart rate quartile was correlated with greater 
relative hazard. Higher beta blocker doses resulted in lower hazard compared across all 
quartiles of heart rate. These findings were consistent after adjusting for age, sex, comorbidities, 
and medications. Figure 4 shows the box-plot graph of the beta blocker dose versus heart rate 
quartiles. The higher beta blocker dose and lower heart rate were both independently and jointly 
associated with lower mortality for all quartiles of heart rate. 
Discussion 
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There are several significant findings from our study. First, in patients with HFrEF use of 
high dose of beta blocker (either carvedilol or metoprolol succinate) was associated with 
improved survival. Second, a lower heart rate on treatment was also associated with lower 
mortality. But even in patients who achieved lower heart rates, a higher beta blocker dose was 
independently associated with lower mortality. Thus, higher beta blocker dose was additive to 
heart rate lowering in reducing long term mortality in HFrEF and was independently associated 
with better survival irrespective of heart rate lowering. 
Although current guidelines recommend up titration of beta blocker therapy to moderate 
to high doses (1, 2), patients in the real world practice and also in clinical trials remain often 
under target.(7, 9) An analysis of the COMET showed that beta blocker dose as well as heart 
rate achieved on beta blocker were independently associated with outcomes.(10) However, in 
real-life situations, the dose of beta blocker used was frequently sub-optimal as shown by the 
data from the OPTIMIZE-HF registry.(11)  
Two studies have shown better clinical outcomes with higher doses of angiotensin 
converting enzyme or angiotensin receptor blockers.(12, 13) However, there has been little 
evidence that beta blocker dose effects clinical outcomes in HF patients.(10, 14, 15) Improved 
outcomes with higher doses of beta blocker could be related to greater antagonism of the 
neurohormonal system, as long-term activation of sympathetic nervous system leads to 
deleterious effects on cardiac function.(16) However, the negative results of a large trial using 
moxonidine, which inhibits sympathetic activation, may cast doubt on this hypothesis.(17) 
Interestingly, ivabradine which decreases heart by blocking If channel rather than sympathetic 
inhibition did not reduce overall mortality when it was added.(18)  
In contrast to McAlister et al.’s meta-regression analysis of beta blockers in HF trials 
which demonstrated that the magnitude of survival benefit seen with beta blockers was 
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associated with the heart rate reduction achieved rather than the dose.(5) Our study 
demonstrated survival benefit with both heart rate reduction and high beta blocker dose similar 
to recent meta-analysis by Kotecha et al. that demonstrated beta blocker dose and achieved 
target heart rate reduced mortality in HFrEF in sinus rhythm.(19)  
The benefits of beta blocker dose have been shown to be dose dependent in the 
REVERT trial which examined the effects of beta blocker therapy on LV remodeling in 
asymptomatic patients. The benefit of LV end-systolic volume index and LVEF were beta 
blocker dose-dependent.(14) Also, the MOCHA study demonstrated that higher doses of beta 
blocker lead to greater improvement in left ventricular ejection fraction and improved 
survival.(15)  
Our results were consistent with a recent post-hoc analysis of the HF-ACTION trial, 
which showed that a higher beta blocker dose was associated with a lower combined endpoint 
of HF hospitalization and death than with reduced heart rate.(7) In addition, this study 
demonstrated that the benefit of heart rate reduction may be independent of the beta blocker 
dose. In contrast to our analysis which included only veterans, the authors had only ambulatory 
patients and excluded patients who were not medically stable. Additionally, changes in beta 
blocker dose and heart rate during follow up were not captured in the study.  
The strengths of our study were that it was a nationwide analysis, large number of 
patients, long follow up and involvement of all patients who receive their care through the VA. 
Study limitations were those that apply to any retrospective analysis in which all confounders 
cannot be accounted for.  Although all subjects had assumed LVEF ≤ 40%, given VA 
restrictions on these medications along with ICD9 diagnosis of HFrEF and similar rates of ICD 
implantation, individual LVEF were not obtained reliably from the database so validation of this 
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assumption was not possible. Also being a study done in the VA system, women were 
underrepresented.   
In conclusion, our study identified that beta blocker dose is associated with improved 
survival independent of achieved HR. The data suggests that up-titration of beta blocker dose 
and heart rate deduction should be aggressively targeted in patients with HFrEF. 
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Figure 1: Kaplan Meier Survival Estimates: High versus Low Beta Blocker dose on Matched 
Sample  
 
Note: Matched on quartiles of heart rate, age, sex, comorbidities, and medications 
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Figure 2: Kaplan Meier Survival Estimates of Heart Rate Quartiles on Matched Sample 
 
 
Note: Matched by beta blocker dose, age, sex, comorbidities, and medications 
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Figure 3: Kaplan Meier Survival Estimates: Beta Blocker Dose and Between Quartiles of 
Average Heart Rate on Matched Sample  
 
 
Note: Matched by quartiles of heart rate, beta blocker dose, age, sex, comorbidities, and 
medications 
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Figure 4: Relative Hazard Ratios by Heart Rate Quartile and Beta Blocker Dose on Matched 
Sample. Matched by quartiles of heart rate, beta blocker dose, age, sex, comorbidities, and 
medications 
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Table 1: Patient Characteristics by Beta Blocker (BB) Dose before and after Matching  
 Pre-matching Post-Matching 
Variable 
Low BB 
Dose 
High BB 
Dose 
p value 
Low BB 
Dose 
High BB 
Dose 
p value 
Total (n=36,168) (n=77,842)  (n=36,168) (n=36,168)  
Age(years) 71.47 66.82 <0.01 71.47 71.40 0.42 
Women 2% 2% <0.01 2% 2% 0.83 
ICD 19% 25% <0.01 19% 18% 0.22 
Atrial fibrillation 34% 35% <0.01 34% 34% 0.08 
Coronary artery disease 61% 66% <0.01 61% 61% 0.21 
Chronic kidney disease 31% 41% <0.01 31% 31% 0.96 
Chronic obstructive 
pulmonary disease 
33% 31% <0.01 33% 32% 0.03 
Cerebrovascular accident 12% 12% <0.01 12% 16% 0.99 
Cirrhosis 2% 2% <0.01 2% 2% 0.65 
Deep vein thrombosis 5% 5% 0.14 5% 5% 0.87 
End stage renal disease 4% 7% <0.01 4% 4% 0.12 
Hypertension 61% 69% <0.01 61% 60% 0.01 
Obstructive sleep apnea 12% 20% <0.01 12% 12% 0.54 
Peripheral arterial disease 23% 24% <0.01 23% 23% 0.09 
Pulmonary embolism 3% 3% 0.18 3% 3% 0.62 
Smoking 24% 25% <0.01 24% 24% 0.76 
Diabetes Mellitus 34% 63% <0.01 34% 34% 0.67 
Medications 
Loop Diuretic 73% 81% <0.01 73% 73% 0.61 
P2Y12 inhibitor 37% 44% <0.01 37% 36% 0.04 
Eplerenone/Spironolactone 25% 36% <0.01 25% 25% 0.30 
Anticoagulant 32% 36% <0.01 32% 32% 0.69 
ACE inhibitor/ARB 90% 95% <0.01 90% 90% 0.14 
Calcium Channel Blocker 36% 49% <0.01 36% 36% 0.73 
Statin 87% 91% <0.01 87% 86% 0.03 
Digoxin 21% 26% <0.01 21% 21% 0.83 
Nitrate 27% 37% <0.01 27% 27% 0.20 
Hydralazine 9% 21% <0.01 9% 9% 0.48 
Aspirin 59% 62% <0.01 59% 58% 0.02 
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Table 2: Cox Proportional Hazard Ratio with Likelihood of Survival of High Dose Beta Blocker 
Compared to Low Dose on Matched Sample 
 
Sample 
Unadjusted Adjusted 
 Hazard 
Ratio  
95% CI p value 
Hazard 
Ratio     
95% CI p value 
 
Overall 
Sample 
0.74 0.73-0.76 <0.01 0.75 0.73-0.77 <0.01 
Metoprolol 
sample only 
0.91 0.88-0.94 <0.01 0.88 0.85-0.91 <0.01 
Carvedilol 
sample only 
0.64 0.62-0.66 <0.01 0.65 0.63-0.67 <0.01 
            
Note: Adjusted for quartiles of heart rate, age, sex, comorbidities, and medications 
 
 
 
Table 3: Hazard Ratio by Heart Rate Quartile and Beta Blocker Dose. The baseline hazard ratio 
is quartile 1 and matched by age, sex, comorbidities, and medications. 
  Unadjusted Adjusted 
Quart
ile 
Mean 
HR 
High Dose (CI) Low Dose (CI) p 
value 
High Dose (CI) Low Dose (CI) p 
value 
1 64 1 (-) 1.34 (1.31-1.37) <0.01 1.25 (1.19-1.31) 1.67 (1.57-1.76) <0.01 
2 71 1.20 (1.19-1.21) 1.61 (1.57-1.65) <0.01 1.51 (1.43-1.59) 2.02 (1.90-2.13) <0.01 
3 77 1.44 (1.41-1.47) 1.94 (1.88-2.00) <0.01 1.83 (1.73-1.93) 2.44 (2.29-2.59) <0.01 
4 87 1.73 (1.68-1.79) 2.33 (2.24-2.42) <0.01 2.21 (2.08-2.34) 2.95 (2.76-3.15) <0.01 
 
 
 
